Categories Uncategorized

Review Finds That Children Develop Mental Health Challenges Post-Concussion

A recent literature review conducted by researchers from the Murdoch Children’s Research Institute has discovered that mental health should be assessed as part of pediatric concussion management and assessment. The review was reported in the “British Journal of Sports Medicine.”

Alice Gornall, a PhD candidate from Monash University and a researcher from MCRI, stated that the relationship between mental health and delayed recovery wasn’t well understood, despite the fact that many mental health and post-concussion symptoms overlap.

The researchers reviewed 69 articles published from 1980 to 2020. The articles involved more than 89,000 children who had experienced concussions. The children were aged 18 and below and were from various countries, including New Zealand, Canada, United States and Australia. The researchers found that sporting injuries and falls were the most common injury cause, which was closely followed by car accidents.

They also discovered that in comparison with children who sustained other injuries and healthy children, almost 37% of these children internalized problems such as post-traumatic stress, depression, anxiety and withdrawal and also externalized issues such as hyperactivity, attention problems and aggression after a concussion.

The researchers also found that pre-existing mental health conditions were a good predictor of mental health problems brought about by concussions. The review noted that 29% of children who had been diagnosed with mental health conditions before their injuries received a new diagnosis after their concussions. In addition, nearly 26% of children who had no previous mental health issues pre-injury went on to develop symptoms.

Gornall stated that considerable improvements in mental health were noted in three to six months after the children had been injured, with a few of them experiencing continuous symptoms for a few years post-injury.

This comes after another study, also led by the Murdoch Children’s Research Institute and reported in the “Journal of Head Trauma Rehabilitation,” discovered that experiencing a traumatic brain injury in early childhood was linked to lower IQ scores.

Gornall stated that concussions were a public health concern as about one-third of children experienced head injuries before they were 13 years old. She added that despite the high occurrence of concussions in adolescents and children, it was still a challenge for clinicians to identify children who were at risk of difficulties post-injury.

Vicki Anderson, PhD., of the MCRI Institute stated that intervention, prevention and assessment of mental health issues after children experienced a concussion should be integrated into the standard management of concussions.

This, Anderson added, was a way to avail adolescents and children with mental health services to either treat issues that already exist or hinder the emergence of unnecessary problems.

Aside from mental health conditions, the human race is also grappling with a rising caseload of people affected by cancer. The race is on to find better cancer treatments, and companies such as Predictive Oncology (NASDAQ: POAI) are focused on making it possible to customize cancer therapies in order to improve treatment outcomes.

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2…

12 hours ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

4 days ago

Pioneering Therapy Could Slow the Effects of Aging

A new groundbreaking therapy could slow down or even reverse aging by recharging body cells…

4 days ago

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Clene Inc. plans to submit a New Drug Application (“NDA”) for lead candidate CNM-Au8® in…

5 days ago

Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors

Scientists at Columbia University have engineered a cancer treatment that leverages bacteria to smuggle cancer-killing…

5 days ago

Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity

FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway…

6 days ago